Journal article

New strategies to direct therapeutic targeting of PML to treat cancers

K Wolyniec, DA Carney, S Haupt, Y Haupt

Frontiers in Oncology | FRONTIERS MEDIA SA | Published : 2013

Abstract

The tumor suppressor function of the promyelocytic leukemia (PML) protein was first identified as a result of its dysregulation in acute promyelocytic leukemia, however, its importance is now emerging far beyond hematological neoplasms, to an extensive range of malignancies, including solid tumors. In response to stress signals, PML coordinates the regulation of numerous proteins, which activate fundamental cellular processes that suppress tumorigenesis. Importantly, PML itself is the subject of specific post-translational modifications, including ubiquitination, phosphorylation, acetylation, and SUMOylation, which in turn control PML activity and stability and ultimately dictate cellular fa..

View full abstract

University of Melbourne Researchers

Grants


Funding Acknowledgements

Due to space limitations, many original important studies have not been cited directly but rather through recent reviews. Ygal Haupt is supported by grants from the National Health and Medical Research Council (NHMRC) of Australia (NHMRC #1026988, #1026999, and 1049179), by a grant from the CASS Foundation, the Victorian Cancer Agency (CAPTIV), PCF, Cancer Council Victoria, and by the VESKI award. Ygal Haupt is NHMRC Senior Research Fellow (NHMRC#628426). The authors declare no conflict of interest.